https://www.selleckchem.com/pr....oducts/pdd00017273.h
In this issue of Med, Sobesky et al. investigate the translational utility of sequencing cell-free DNA to describe genetic features of classic Hodgkin Lymphoma (HL) and to evaluate minimal residual disease (MRD) for patients treated in a clinical trial1.Liquid biopsy detection of residual cancer after therapy offers to transform oncology care. Nonetheless, in the residual cancer context, signals are sparse and are hindered by technical sequencing noise. Kurtz et al.1 introduce phased variant enrichment and detection sequencing (phas
Like
Comment
Share
